Found: 7
Select item for more details and to access through your institution.
The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea.
- Published in:
- Pharmacology Research & Perspectives, 2019, v. 7, n. 5, p. 1, doi. 10.1002/prp2.521
- By:
- Publication type:
- Article
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 175, n. 1, p. 5, doi. 10.1007/s10549-018-05102-x
- By:
- Publication type:
- Article
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 3, p. e442, doi. 10.1016/j.cllc.2020.06.011
- By:
- Publication type:
- Article
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 1, p. 13, doi. 10.1002/onco.13977
- By:
- Publication type:
- Article
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 1, p. 22, doi. 10.1002/onco.13976
- By:
- Publication type:
- Article